- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05351541
Psilocybinterapi för kronisk ländryggssmärta (POP)
En dubbelblind, randomiserad studie som undersöker den preliminära effekten av psilocybinterapi för personer med kronisk ländryggssmärta
This study evaluates whether psilocybin therapy helps patients cope with chronic low back pain more effectively. Patients may be recruited at Stanford and University of California San Francisco (UCSF), study procedures will occur at UCSF. Each participant will receive a dose of psilocybin with possibly one or more other drugs. Participants will undergo two preparation sessions, a dosing session, three integration sessions to discuss their psilocybin experience, and several follow up sessions.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Chronic pain is associated with higher levels of pain-related distress, depression, emotional dysfunction, helplessness, hopelessness, and suicidality. Psilocybin is a psychoactive drug that may be well-suited to easing the psychological and emotional symptoms of distress associated with chronic pain. Previous studies testing psilocybin therapy have shown improvements on multiple behavioral and psychiatric outcomes, but it is unknown whether psilocybin therapy similarly enables patients to cope with chronic pain more effectively. The investigators will determine whether psilocybin therapy improves patients' ability to cope with chronic low back pain. If psilocybin therapy is an effective treatment in this population, its use could be incorporated into interventions for chronic low back pain and other psychological conditions.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studieorter
-
-
California
-
San Francisco, California, Förenta staterna, 94107
- University of California San Francisco
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age 25 to 70 years old
- Comfortable speaking and writing in English
- Diagnosed with chronic low back pain
- Able to attend all in-person visits at UCSF as well as virtual visits
- Has tried at least two previous medications/ procedures and physical therapy trials for low back pain
Exclusion Criteria:
- Chronic low back pain that is attributed to malignancy, subacute or acute fracture or infection
- Low back pain with radiation below the knee
- Low back pain with neurologic signs present
- Regular use of medications that may have problematic interactions with psilocybin, including but not limited to dopamine agonists, MAO inhibitors, antipsychotics, and stimulants
- A health condition that makes study unsafe or unfeasible, determined by study physicians
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Psilocybin in combination with Zolpidem and Modafinil
Single dose of Psilocybin (1mg-30mg) in combination with zolpidem and modafinil |
1-30 mg (oral administration), Modafinil (oral administration), and Zolpidem (oral administration)
Andra namn:
|
|
Experimentell: Psilocybin in combination with Zolpidem
Single dose of Psilocybin (1mg-30mg) in combination with zolpidem |
1-30 mg (oral administration), Zolpidem (oral administration), and placebo (oral administration)
Andra namn:
|
|
Experimentell: Psilocybin in combination with Modafinil
Single dose of Psilocybin (1mg-30mg) in combination with modafinil |
1-30 mg (oral administration), Modafinil (oral administration), and placebo (oral administration)
Andra namn:
|
|
Experimentell: Psilocybin in combination with Placebo
Single dose of Psilocybin (1mg-30mg) in combination with placebo |
1-30 mg (oral administration), and placebo (oral administration)
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in pain interference
Tidsram: Baseline, 1-month after psilocybin session
|
The Brief Pain Inventory-Interference subscale (BPI) will be used to assess how pain interferes with a variety of daily activities (e.g., walking, lifting, mood, sleep, relationships). Seven items are rated on a scale from 0 (does not interfere) to 10 (completely interferes) for a total possible score ranging from 0 to 70. Higher scores represent greater interference from pain. |
Baseline, 1-month after psilocybin session
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in pain interference
Tidsram: Baseline, 1-week, and 3-months
|
The Brief Pain Inventory-Interference subscale (BPI) will be used to assess how pain interferes with a variety of daily activities (e.g., walking, lifting, mood, sleep, relationships). Seven items are rated on a scale from 0 (does not interfere) to 10 (completely interferes) for a total possible score ranging from 0 to 70. Higher scores represent greater interference from pain. |
Baseline, 1-week, and 3-months
|
|
Change in average pain intensity
Tidsram: Baseline, 1-week, 1-month, and 3-months after psilocybin session
|
The Brief Pain Inventory with the Michigan Body Map will be used to assess pain location and worst, least, average, and present pain on a numerical rating scale from 0 (no pain) to 10 (pain as bad as you can imagine) over the past 24 hours, where higher scores represent greater pain intensity. |
Baseline, 1-week, 1-month, and 3-months after psilocybin session
|
|
Change in clinical depressive symptom severity
Tidsram: Baseline, 1-week, 1-month, and 3-months after psilocybin session
|
The 17-item clinician administered Hamilton Rating Scale for Depression will be used to assess changes in the severity of depressive symptoms. Each item is scored by a clinician on a 3- or 5-point scale from 0 (Not present) to 4 (severe) and summed for a total score between 0 and 52. A higher total score represents greater depressive symptom severity. |
Baseline, 1-week, 1-month, and 3-months after psilocybin session
|
|
Change in depressive symptom severity
Tidsram: Baseline, pre-dosing session, 5-days, 11-days, and 77-days after psilocybin session
|
The 7-item PROMIS-Depression self-report scale will be used as an additional indicator for changes in depression symptom severity. Items are endorsed on a 5-point scale ranging from 1 (Never) to 5 (Always). A higher total score represents greater depressive symptom severity. |
Baseline, pre-dosing session, 5-days, 11-days, and 77-days after psilocybin session
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Joshua Woolley, University of California, San Francisco
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Smärta
- Neurologiska manifestationer
- Patologiska tillstånd, tecken och symtom
- Tecken och symtom
- Kronisk smärta
- Organiska kemikalier
- Pyridiner
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Kolväten
- Kolväten, cykliska
- Kolväten, aromatisk
- Bensiverivat
- Benshydrylföreningar
- Zolpidem
- Modafinil
Andra studie-ID-nummer
- 20-21441
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .